Core Viewpoint - Beijing Yuewei Medical Technology Co., Ltd. has completed nearly 100 million yuan in Series B financing, aiming to enhance its research and market penetration in cardiovascular surgery and related fields, thereby solidifying its leading position in the industry [2]. Group 1: Company Overview - Yuewei Medical was founded in September 2021 and has developed multiple innovative medical devices that fill market gaps, including nearly 10 products in coronary surgery, critical care, and extracorporeal circulation [2]. - The company has created a product line that includes domestically innovative products such as the ultrasonic vascular flow measurement system and the pulsatile left ventricular assist device [2][4]. Group 2: Investment and Growth Strategy - The recent financing round led by Yifeng Capital, with participation from Beishang Capital and Bohai Chuangfu, will support Yuewei Medical's product development and market expansion [2]. - The company has demonstrated a strong capability for business expansion and mergers, planning to enter the DVT product line through acquisitions by 2025, with two innovative medical devices already in the clinical registration phase [2]. Group 3: Clinical and Market Position - The founding team of Yuewei Medical combines clinical experts and industry veterans, employing a "medical-engineering integration" model to address core clinical pain points in cardiovascular surgery [3]. - The company has established a gradient product pipeline that includes AI diagnostics and high-end innovative devices, showcasing its systematic innovation driven by clinical needs [4].